PremiumThe FlyEdgewise Therapeutics downgraded to Sector Perform from Outperform at Scotiabank Edgewise Therapeutics 9.935M share Spot Secondary priced at $20.13 Edgewise Therapeutics Announces $200M Stock Offering PremiumThe FlyEdgewise Therapeutics initiated with an Outperform at Scotiabank Edgewise Therapeutics: Promising Pipeline and Upcoming Data Readouts Reinforce Buy Rating Edgewise Therapeutics Reports 2024 Financial Results and Progress PremiumThe Flydgewise Therapeutics placed on ‘Positive Catalyst Watch’ at JPMorgan Edgewise Therapeutics Promotes Derakhshan to COO Role Edgewise Therapeutics promotes Behrad Derakhshan to COO 
